Forskning ved Københavns Universitet - Københavns Universitet

Forside

Insulin-like growth factor 1 and growth hormone in chronic liver disease.

Publikation: Bidrag til tidsskriftReviewForskning

Standard

Insulin-like growth factor 1 and growth hormone in chronic liver disease. / Møller, Søren; Becker, Povl Ulrik.

I: Digestive Diseases, Bind 10, Nr. 4, 1992, s. 239-248.

Publikation: Bidrag til tidsskriftReviewForskning

Harvard

Møller, S & Becker, PU 1992, 'Insulin-like growth factor 1 and growth hormone in chronic liver disease.', Digestive Diseases, bind 10, nr. 4, s. 239-248.

APA

Møller, S., & Becker, P. U. (1992). Insulin-like growth factor 1 and growth hormone in chronic liver disease. Digestive Diseases, 10(4), 239-248.

Vancouver

Møller S, Becker PU. Insulin-like growth factor 1 and growth hormone in chronic liver disease. Digestive Diseases. 1992;10(4):239-248.

Author

Møller, Søren ; Becker, Povl Ulrik. / Insulin-like growth factor 1 and growth hormone in chronic liver disease. I: Digestive Diseases. 1992 ; Bind 10, Nr. 4. s. 239-248.

Bibtex

@article{15103091d8ad44ddbd5234152d0bbd7c,
title = "Insulin-like growth factor 1 and growth hormone in chronic liver disease.",
abstract = "Somatomedins or insulin-like growth factors (IGF) are peptides synthesized in the liver. IGFs have different anabolic and metabolic actions and are important in normal growth and development. The concentration of insulin-like growth factor 1 (IGF-1) is low in patients with chronic liver disease mainly due to the decreased liver function. Low levels of somatomedins are also seen in patients with growth hormone (GH) insufficiency, renal impairment, and malnutrition. GH stimulates the production of IGF-1, and both are part of a negative feedback system acting on hepatic, pituitary, and hypothalamic levels. The basal and stimulated GH concentration is pathologically elevated in patients with chronic liver disease and may be due to a disturbed regulation. Alterations in liver IGF receptors in patients with chronic liver disease still require investigation as they may be important for the liver function.",
author = "S{\o}ren M{\o}ller and Becker, {Povl Ulrik}",
year = "1992",
language = "English",
volume = "10",
pages = "239--248",
journal = "Digestive Diseases",
issn = "0257-2753",
publisher = "S Karger AG",
number = "4",

}

RIS

TY - JOUR

T1 - Insulin-like growth factor 1 and growth hormone in chronic liver disease.

AU - Møller, Søren

AU - Becker, Povl Ulrik

PY - 1992

Y1 - 1992

N2 - Somatomedins or insulin-like growth factors (IGF) are peptides synthesized in the liver. IGFs have different anabolic and metabolic actions and are important in normal growth and development. The concentration of insulin-like growth factor 1 (IGF-1) is low in patients with chronic liver disease mainly due to the decreased liver function. Low levels of somatomedins are also seen in patients with growth hormone (GH) insufficiency, renal impairment, and malnutrition. GH stimulates the production of IGF-1, and both are part of a negative feedback system acting on hepatic, pituitary, and hypothalamic levels. The basal and stimulated GH concentration is pathologically elevated in patients with chronic liver disease and may be due to a disturbed regulation. Alterations in liver IGF receptors in patients with chronic liver disease still require investigation as they may be important for the liver function.

AB - Somatomedins or insulin-like growth factors (IGF) are peptides synthesized in the liver. IGFs have different anabolic and metabolic actions and are important in normal growth and development. The concentration of insulin-like growth factor 1 (IGF-1) is low in patients with chronic liver disease mainly due to the decreased liver function. Low levels of somatomedins are also seen in patients with growth hormone (GH) insufficiency, renal impairment, and malnutrition. GH stimulates the production of IGF-1, and both are part of a negative feedback system acting on hepatic, pituitary, and hypothalamic levels. The basal and stimulated GH concentration is pathologically elevated in patients with chronic liver disease and may be due to a disturbed regulation. Alterations in liver IGF receptors in patients with chronic liver disease still require investigation as they may be important for the liver function.

M3 - Review

VL - 10

SP - 239

EP - 248

JO - Digestive Diseases

JF - Digestive Diseases

SN - 0257-2753

IS - 4

ER -

ID: 34106210